Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Protein vs Protein+Peptide Vaccine in Metastatic Melanoma
NCT00072085Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2003
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant gp100 protein in melanoma, sponsored by National Cancer Institute. Started Sep 2003; status: completed.
02
Drugs
recombinant gp100 protein
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00072085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072085.